Literature DB >> 3508552

Analysis of in vitro dissolution of whole vs. half controlled-release theophylline tablets.

V P Shah1, L A Yamamoto, D Schuirman, J Elkins, J P Skelly.   

Abstract

Controlled-release (CR) drug products dissolve more slowly than conventional-release products, reflecting their quality of sustaining a prolonged therapeutic effect. A frequent practice with scored tablets when only half the dosage is desired is to divide the tablet at the score mark and administer only half of the product. The dissolution characteristics of the divided tablets are unknown. It is only an assumption that the halved tablet behaves similarly to the whole tablet both in vitro and in vivo. A series of in vitro dissolution analyses was performed on whole and half CR theophylline tablets from different manufacturers. Statistical tests were carried out between the dissolution results of whole and those of halved tablets to determine whether the mean overall percentages dissolution (averaged over sampling times) were similar and whether the patterns of percentage dissolution over time were similar. The dissolution of halved tablets was slightly faster compared to that of intact (whole) tablets. However, these small differences were not large enough to cause concern or to require bioavailability studies.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3508552     DOI: 10.1023/a:1016442514205

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  3 in total

Review 1.  Use of statistical methods in evaluation of in vivo performance of dosage forms.

Authors:  W J Westlake
Journal:  J Pharm Sci       Date:  1973-10       Impact factor: 3.534

2.  Dissolution and bioavailability studies of whole and halved sustained-release theophylline tablets.

Authors:  K J Simons; E M Frith; F E Simons
Journal:  J Pharm Sci       Date:  1982-05       Impact factor: 3.534

3.  Relative bioavailability and release pattern of whole and halved sustained-release theophylline tablets.

Authors:  N H Leeds; P Gal; A A Purohit; J B Walter
Journal:  Clin Pharm       Date:  1982 Mar-Apr
  3 in total
  3 in total

1.  In vitro and in vivo evaluation of whole and half tablets of sustained-release adinazolam mesylate.

Authors:  J W Skoug; M T Borin; J C Fleishaker; A M Cooper
Journal:  Pharm Res       Date:  1991-12       Impact factor: 4.200

2.  In vitro dissolution profile comparison--statistics and analysis of the similarity factor, f2.

Authors:  V P Shah; Y Tsong; P Sathe; J P Liu
Journal:  Pharm Res       Date:  1998-06       Impact factor: 4.200

Review 3.  Emergence of 3D Printed Dosage Forms: Opportunities and Challenges.

Authors:  Mohamed A Alhnan; Tochukwu C Okwuosa; Muzna Sadia; Ka-Wai Wan; Waqar Ahmed; Basel Arafat
Journal:  Pharm Res       Date:  2016-05-18       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.